Projects View

AGC Biologics to Invest 50 Billion Japanese yen for New Manufacturing Plant in Yokohama, Japan

Specifications:

Name:

AGC Biologics to Invest 50 Billion Japanese yen for New Manufacturing Plant in Yokohama, Japan

Location:

Yokohama, Japan

Company:

AGC Biologics

Estimated Cost:

50 Billion Japanese yen

Source:

https://www.agcbio.com

Introduction:

AGC Biologics plans to establish a cutting-edge manufacturing facility at AGC Inc.’s Yokohama Technical Center in Japan.

Features:

The new AGC Biologics Yokohama facility will provide comprehensive services from pre-clinical to commercial stages for mammalian-based protein biologics, cell therapies, and messenger RNA (mRNA). It will accommodate multiple 2,000 L single-use bioreactors and several 4,000 L or larger reactors for mammalian cell culture services, positioning it as one of Japan’s largest facilities for mammalian-based manufacturing capacity upon completion (as estimated by AGC).

This expansion is a pivotal component of our strategic growth initiative aimed at enhancing pharmaceutical development and manufacturing capabilities in Asia to meet the global demand for biologics and advanced therapy medicinal products (ATMPs). Operations are slated to commence in 2026.

The Yokohama facility will play a crucial role in serving regional and global developers seeking biopharmaceutical development and manufacturing capabilities. It will also optimize operational efficiency and enhance supply chain capabilities across AGC Biologics' global network. Currently, our Chiba facility in the region offers mammalian expression and microbial fermentation services.